Intellipharmaceutics international inc. (IPCI)
Income statement / Quarterly
Aug'18May'18Nov'17Aug'17May'17Feb'17May'16Feb'16Feb'14Feb'13
Revenues
Licensing (Note 3)

320

489

-

1,114

1,926

-

-

-

-

-

Licensing (Note 3)

-

-

-

-

-

-

-

-

4,435

-

Milestone (Note 3)

-

-

-

-

-

-

-

-

245

-

Up-front fees (Note 3)

93

86

-

75

75

-

-

-

-

-

Revenues

413

576

-

1,189

2,001

-

-

-

4,681

-

Cost of good sold
Cost of goods sold

45

65

-

376

211

-

-

-

-

-

Gross Margin

368

511

-

813

1,790

-

-

-

-

-

Expenses
Research and development

3,324

2,195

-

2,298

2,677

-

-

-

1,357

1,337

Selling, general and administrative

792

967

-

756

756

-

-

-

1,006

833

Depreciation

155

153

-

126

106

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

71

93

Expenses

4,271

3,316

-

3,181

3,541

-

-

-

2,435

2,264

Loss from operations

-3,903

-2,805

-

-2,368

-1,750

-

-

-

-

-

Loss from operations

-

-

-

-

-

-

-

-

2,245

-2,264

Fair value adjustment of derivative liabilities

-

-

-

-

-

-

-

-

-

1,232

Net foreign exchange gain (loss)

9

7

-

-90

33

-

-

-

38

-242

Interest income

0

0

-

0

15

-

-

-

0

0

Interest expense

59

61

-

91

103

-

-

-

82

65

Net loss and comprehensive loss

-3,954

-2,859

-

-2,550

-1,805

-

-

-

2,201

-1,340

Foreign exchange translation adjustment

-

-

-

-

-

-

-

-

-

242

Comprehensive loss

-

-

-

-

-

-

-

-

2,201

-1,097

Loss per common share, basic and diluted

-0.91

-0.07

0.67

-0.83

-0.06

-0.07

-0.08

-0.09

-

-

Weighted average number of common shares outstanding, basic and diluted

4,353

41,838

60,631

3,071

30,388

29,966

24,752

24,431

-

-

Basic (in Dollars per share)

-

-

-

-

-

-

-

-

0.10

-0.07

Diluted (in Dollars per share)

-

-

-

-

-

-

-

-

0.09

-0.07

Basic (in Shares)

-

-

-

-

-

-

-

-

22,280

17,906

Diluted (in Shares)

-

-

-

-

-

-

-

-

23,561

17,906